Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $(0.07) by 1142.86 percent. This is a 173.74 percent increase over losses of $(0.99) per share from the same period last year. The company reported quarterly sales of $413.464 million which beat the analyst consensus estimate of $373.283 million by 10.76 percent. This is a 63.10 percent increase over sales of $253.500 million the same period last year.
Sarepta Therapeutics Q1 2024 Adj EPS $0.73 Beats $(0.07) Estimate, Sales $413.464M Beat $373.283M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.